ASH 2020 | HORIZON study: EMD subgroup analysis
Paul Richardson
• 6 Dec 2020
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase II HORIZON study (NCT02963493), investigating melflufen plus dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD). This patient subgroup has a highly unmet medical need with very poor prognosis and clinical outcomes. The combination of dex and melflufen, a first-in-class peptide-drug conjugate (PDC), showed clinically meaningful efficacy, as well as a manageable safety profile. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
